Display options
Cite
Ammendola M, Sacco R, Sammarco G, et al. Mast cells positive to tryptase, endothelial cells positive to protease-activated receptor-2, and microvascular density correlate among themselves in hepatocellular carcinoma patients who have undergone surgery. Onco Targets Ther. 2016;9:4465-71doi: 10.2147/OTT.S105368.
Ammendola, M., Sacco, R., Sammarco, G., Piardi, T., Zuccalà, V., Patruno, R., Zullo, A., Zizzo, N., Nardo, B., Marech, I., Crovace, A., Gadaleta, C. D., Pessaux, P., & Ranieri, G. (2016). Mast cells positive to tryptase, endothelial cells positive to protease-activated receptor-2, and microvascular density correlate among themselves in hepatocellular carcinoma patients who have undergone surgery. OncoTargets and therapy, 94465-71. https://doi.org/10.2147/OTT.S105368
Ammendola, Michele, et al. "Mast cells positive to tryptase, endothelial cells positive to protease-activated receptor-2, and microvascular density correlate among themselves in hepatocellular carcinoma patients who have undergone surgery." OncoTargets and therapy vol. 9 (2016): 4465-71. doi: https://doi.org/10.2147/OTT.S105368
Ammendola M, Sacco R, Sammarco G, Piardi T, Zuccalà V, Patruno R, Zullo A, Zizzo N, Nardo B, Marech I, Crovace A, Gadaleta CD, Pessaux P, Ranieri G. Mast cells positive to tryptase, endothelial cells positive to protease-activated receptor-2, and microvascular density correlate among themselves in hepatocellular carcinoma patients who have undergone surgery. Onco Targets Ther. 2016 Jul 21;9:4465-71. doi: 10.2147/OTT.S105368. eCollection 2016. PMID: 27499640; PMCID: PMC4959580.
Copy Download .nbib Format: NLM
Share it on

Onco Targets Ther. 2016 Jul 21;9:4465-71. doi: 10.2147/OTT.S105368. eCollection 2016.

Mast cells positive to tryptase, endothelial cells positive to protease-activated receptor-2, and microvascular density correlate among themselves in hepatocellular carcinoma patients who have undergone surgery.

OncoTargets and therapy

Michele Ammendola, Rosario Sacco, Giuseppe Sammarco, Tullio Piardi, Valeria Zuccalà, Rosa Patruno, Alessandra Zullo, Nicola Zizzo, Bruno Nardo, Ilaria Marech, Alberto Crovace, Cosmo Damiano Gadaleta, Patrick Pessaux, Girolamo Ranieri

Affiliations

  1. Department of Medical and Surgical Sciences, General Surgery Unit, University of Catanzaro "Magna Graecia" Medical School, Catanzaro, Italy.
  2. Department of General, Digestive and Endocrine Surgery, Hopital Robert Debre, Centre Hospitalier Universitaire de Reims, Universite de Reims Champagne-Ardenne, Reims, France.
  3. Department of Health Science, Pathology Unit, University of Catanzaro "Magna Graecia" Medical School, Catanzaro.
  4. Chair of Pathology, Veterinary Medical School, University "Aldo Moro", Bari.
  5. Department of Medical and Surgery Sciences, S Orsola Hospital, University of Bologna, Bologna.
  6. Interventional Radiology Unit with Integrated Section of Translational Medical Oncology, National Cancer Research Centre, "Giovanni Paolo II"
  7. Department of Emergency and Organ Transplantation (DETO), Veterinary Medical School, University "Aldo Moro", Bari, Italy.
  8. Hepato-Biliary and Pancreatic Surgical Unit, General, Digestive and Endocrine Surgery, IRCAD, IHU Mix-Surg, Institute for Minimally Invasive Image-Guided Surgery, University of Strasbourg, Strasbourg, France.

PMID: 27499640 PMCID: PMC4959580 DOI: 10.2147/OTT.S105368

Abstract

BACKGROUND: Mast cells (MCs) can stimulate angiogenesis, releasing several proangiogenic cytokines stored in their cytoplasm. In particular MCs can release tryptase, a potent in vivo and in vitro proangiogenic factor via proteinase-activated receptor-2 (PAR-2) activation and mitogen-activated protein kinase phosphorylation. Nevertheless, no data are available concerning the relationship between MC density positive to tryptase (MCDPT), endothelial cells positive to PAR-2 forming microvascular density (PAR-2-MVD), and classical MVD (C-MVD) in hepatocellular carcinoma (HCC) angiogenesis. This study analyzed the correlation between MCDPT, PAR-2-MVD, and C-MVD, each correlated to the others and to the main clinicopathological features, in early HCC patients who underwent surgery.

METHODS: A series of 53 HCC patients with early stage (stage 0 according to the Barcelona Clinic Liver Cancer Staging Classification) were selected and then underwent surgery. Tumor tissue samples were evaluated by means of immunohistochemistry and image analysis methods in terms of number of MCDPT, PAR-2-MVD, and C-MVD.

RESULTS: A significant correlation between MCDPT, PAR-2-MVD, and C-MVD groups, each correlated to the others, was found by Pearson t-test analysis (r ranged from 0.67 to 0.81; P-value ranged from 0.01 to 0.03). No other significant correlation was found.

CONCLUSION: Our in vivo pilot data suggest that MCDPT and PAR-2-MVD may play a role in HCC angiogenesis and could be further evaluated as a target of antiangiogenic therapy.

Keywords: stromal cells; translational research; tumour angiogenesis

References

  1. J Cell Mol Med. 2013 Aug;17(8):1025-37 - PubMed
  2. Exp Cell Res. 2015 Mar 15;332(2):157-62 - PubMed
  3. Semin Liver Dis. 2010 Feb;30(1):61-74 - PubMed
  4. Am J Pathol. 2013 Aug;183(2):566-75 - PubMed
  5. J Cell Mol Med. 2007 Mar-Apr;11(2):362-8 - PubMed
  6. J Cancer Res Clin Oncol. 2011 Jun;137(6):965-73 - PubMed
  7. J Hepatol. 2000 Dec;33(6):961-6 - PubMed
  8. World J Gastroenterol. 2014 Apr 21;20(15):4141-50 - PubMed
  9. Int J Dev Biol. 2011;55(1):99-102 - PubMed
  10. J Leukoc Biol. 1998 Mar;63(3):337-41 - PubMed
  11. Physiol Res. 2007;56(4):475-84 - PubMed
  12. Gastroenterol Res Pract. 2014;2014:951957 - PubMed
  13. Crit Rev Oncol Hematol. 2014 Jul;91(1):98-111 - PubMed
  14. Mol Clin Oncol. 2013 Mar;1(2):385-389 - PubMed
  15. Oncol Lett. 2014 Jul;8(1):379-383 - PubMed
  16. J Clin Invest. 1997 Jun 1;99(11):2691-700 - PubMed
  17. J Pathol. 2006 Jun;209(2):147-56 - PubMed
  18. Oncology. 2013;85(2):111-6 - PubMed
  19. BMC Cancer. 2014 Jul 24;14:534 - PubMed
  20. Eur J Pharmacol. 2016 May 5;778:146-51 - PubMed
  21. Int J Mol Sci. 2015 Feb 02;16(2):3237-50 - PubMed
  22. World J Gastroenterol. 2003 Jul;9(7):1469-73 - PubMed
  23. J Biol Chem. 1994 Apr 1;269(13):9416-9 - PubMed
  24. Trends Immunol. 2004 May;25(5):235-41 - PubMed
  25. Br J Cancer. 2001 Sep 1;85(5):772-9 - PubMed
  26. PLoS One. 2012;7(9):e46087 - PubMed
  27. Am J Physiol Renal Physiol. 2005 Apr;288(4):F714-21 - PubMed
  28. Cancer Lett. 2016 Sep 28;380(1):216-26 - PubMed
  29. Eur J Intern Med. 2014 Jun;25(5):430-7 - PubMed
  30. Biomed Res Int. 2014;2014:154702 - PubMed
  31. Clin Exp Immunol. 2009 Feb;155(2):140-6 - PubMed
  32. Biochem Biophys Res Commun. 2006 Jun 16;344(4):1263-70 - PubMed
  33. Gastroenterol Res Pract. 2013;2013:703163 - PubMed
  34. J Pharmacol Sci. 2003 Aug;92(4):420-3 - PubMed
  35. Exp Mol Pathol. 2013 Feb;94(1):91-7 - PubMed
  36. APMIS. 2002 May;110(5):355-71 - PubMed
  37. Cancer Res. 2006 Jan 1;66(1):307-14 - PubMed
  38. Biochem Pharmacol. 2001 Feb 1;61(3):271-6 - PubMed
  39. Chem Immunol Allergy. 2014;99:15-36 - PubMed
  40. Int J Endocrinol. 2015;2015:705169 - PubMed
  41. J Hepatobiliary Pancreat Sci. 2010 Jul;17(4):440-2 - PubMed
  42. PLoS One. 2010 Mar 04;5(3):e9430 - PubMed
  43. Dis Markers. 2011;31(3):181-90 - PubMed
  44. PLoS One. 2014 Jun 10;9(6):e99512 - PubMed
  45. Updates Surg. 2013 Mar;65(1):53-7 - PubMed
  46. Arterioscler Thromb Vasc Biol. 2007 Jun;27(6):1456-62 - PubMed
  47. Int J Oncol. 2009 Jul;35(1):115-20 - PubMed
  48. Ann Surg. 2011 Mar;253(3):453-69 - PubMed
  49. World J Gastroenterol. 2014 Jul 21;20(27):8910-20 - PubMed
  50. J Immunol. 2003 Aug 1;171(3):1493-9 - PubMed
  51. J Pharmacol Sci. 2005 Jan;97(1):14-9 - PubMed
  52. J Gastroenterol Hepatol. 2009 Jul;24(7):1265-75 - PubMed
  53. Crit Rev Oncol Hematol. 2011 Oct;80(1):40-53 - PubMed

Publication Types